TNFSF8 Human

CD30 Ligand is a type II membrane protein, meaning it has a single transmembrane domain with its N-terminus located inside the cell and its C-terminus outside . The human recombinant form of CD30 Ligand is typically produced in a laboratory setting using various expression systems, such as HEK293 cells or mouse myeloma cell lines . The recombinant protein is often tagged with a histidine tag to facilitate purification and detection .

CD30 Ligand interacts specifically with its receptor, CD30, which is a member of the TNF receptor superfamily . This interaction plays a crucial role in the regulation of immune responses, including cell proliferation, activation, differentiation, and apoptosis . CD30-CD30 Ligand signaling is particularly important in the context of T cell-dependent immune responses and has been implicated in various pathological conditions, including Hodgkin lymphoma, large cell anaplastic lymphomas, and Burkitt lymphomas .

Due to its significant role in immune regulation and its involvement in various hematologic malignancies, CD30 Ligand and its receptor CD30 are considered potential therapeutic targets . Research into CD30 Ligand has led to the development of therapeutic antibodies and other biologics aimed at modulating CD30-CD30 Ligand interactions for the treatment of cancers and autoimmune diseases .

In the laboratory, recombinant CD30 Ligand is used in various assays to study its biological activities. For example, it has been shown to stimulate interleukin-6 (IL-6) secretion by Hodgkin’s lymphoma cells . This makes it a valuable tool for understanding the mechanisms underlying immune responses and for developing new therapeutic strategies.